0
Abstract: Poster Presentations |

LOWER RESPIRATORY TRACT BIOCHEMICAL EFFICACY OF INTRAVENOUS ADMINISTRATION OF A NEW FORM OF HIGHLY PURIFIED ALPHA1-ANTITRYPSIN FREE TO VIEW

L. T. Spencer, MD*; David P. Pollock, MD; James M. Stocks, MD; Mark L. Brantly, MD
Author and Funding Information

University of Florida College of Medicine, Gainesville, FL


Chest


Chest. 2005;128(4_MeetingAbstracts):261S. doi:10.1378/chest.128.4_MeetingAbstracts.261S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  To evaluate the biochemical efficacy and safety of a new source of highly purified, plasma derived alpha1-proteinase inhibitor (A1-PI) in individuals with alpha1-antitrypsin (AAT) deficiency.

METHODS:  A randomized, double-blind study compared Zemaira® (ZLB Behring LLC) [Z] with Prolastin® (Bayer Corporation) [P]. Patients received either Z or P (randomized 2:1) for 10 weeks by intravenous infusion (60 mg/kg functionally active A1-PI weekly). The P group was then crossed over to an open-label phase where all subjects received Z for 14 weeks. A subset of 15 patients with forced expiratory volume in 1 second ≥50% predicted underwent bronchoalveolar lavage. Antigenic AAT levels and AAT:neutrophil elastase (AAT:NE) complexes in the epithelial lining fluid (ELF) between baseline and Week 11 were measured by ELISA.

RESULTS:  Increases in ELF AAT levels were statistically significant in both treatment groups. Subjects receiving Z A1-PI had ELF values of 197.1 nM at baseline, increasing to 1125.5 nM after 10 weeks of treatment (p<0.0001), and those receiving P increased from 261.5 nM to 1192.5 nM (p=0.0121). Z A1-PI remained functionally active when delivered to the lung from the systemic circulation, as indicated by significant increases in ELF AAT:NE complexes from baseline to 11 weeks [2.8 nM to 66.8 nM (p=0.0012)]. Both Z and P were safely tolerated.

CONCLUSION:  The results indicate that both protein preparations are delivered to the lung in an equivalent manner after intravenous administration and that the exogenous protein is in a functional state capable of forming complexes with NE in the lung.

CLINICAL IMPLICATIONS:  Z intravenous augmentation therapy is associated with reconstitution of lower respiratory protease-anti-protease homeostasis similar to P. AUC variable (μM*day)Median (range)Ratio of Z(A1-PI): P(A1-PI)90% CIZ(A1-PI)P(A1-PI)AUD0-21129 (93 –171)140 (101 –194)92.4%88.5% - 96.5%AUD0-∞134 (96 –190)147 (104 - 214)92.0%84.9% - 99.7%

DISCLOSURE:  L Spencer, Consultant fee, speaker bureau, advisory committee, etc. LTS and MB have been scientific advisors to Aventis Berhing and Bayer Healthcare.; Other DPP and JMS have no financial disclosures.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543